Abstract
The development of the immunomodulatory drug lenalidomide, along with proteasome inhibitors, has revolutionised the treatment of multiple myeloma since the early 2000s. Lenalidomide is now used in triplet or quadruplet combination therapeutic approaches for patients with newly diagnosed and relapsed myeloma. Lenalidomide has also been shown to prolong progression-free survival and overall survival as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT). The approved indications for lenalidomide now include other haematological malignancies such as myelodysplastic syndrome with an isolated del(5q), mantle cell lymphoma, and follicular lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
